Voltammetric behavior of antileukemia drug glivec. Part I - Electrochemical study of Glivec

被引:20
作者
Diculescu, Victor Constantin
Vivan, Marilene
Brett, Ana Maria Oliveira [1 ]
机构
[1] Univ Coimbra, Dept Quim, Fac Ciencias & Tecnol, P-3004535 Coimbra, Portugal
[2] Hosp Univ Coimbra, P-3000 Coimbra, Portugal
关键词
glivec; chronic myelogenous leukemia (CML); electrochemistry; voltammetry; adsorption;
D O I
10.1002/elan.200603591
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
The electrochemical behavior of the antileukemia drug glivec was investigated at a glassy carbon electrode (GCE). The oxidation is a complex, pH-dependent, irreversible electrode process involving the transfer of 2 electrons and 2 protons and the formation of an electroactive product, P-glivec, which strongly adsorbs on the GCE surface and undergoes reversible oxidation. The adsorption of P-glivec at the GCE surface yields a compact monolayer that inhibits further oxidation of glivec. The electrochemical reduction is a simple pH dependent irreversible process involving the transfer of 2 electrons and 2 protons and occurs with the formation of a nonelectroactive product. The diffusion coefficient of glivec was calculated to be D-O = 7.35 x 10(-6) cm(2) s(-1) in pH 4.5 0.1 M acetate buffer.
引用
收藏
页码:1800 / 1807
页数:8
相关论文
共 28 条
[1]   High-throughput quantification of the anti-leukemia drug ST1571 (Gleevec™) and its main metabolite (CGP 74588) in human plasma using liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Lohne, J ;
Ramos, L ;
Khemani, L ;
Hayes, M ;
Tse, F .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2002, 768 (02) :325-340
[2]   Quantification of the anti-leukemia drug ST1571 (Gleevec™) and its metabolite (CGP 74588) in monkey plasma using a semi-automated solid phase extraction procedure and liquid chromatography-tandem mass spectrometry [J].
Bakhtiar, R ;
Khemani, L ;
Hayes, M ;
Bedman, T ;
Tse, F .
JOURNAL OF PHARMACEUTICAL AND BIOMEDICAL ANALYSIS, 2002, 28 (06) :1183-1194
[3]   Tyrosine kinase receptors as attractive targets of cancer therapy [J].
Bennasroune, A ;
Gardin, A ;
Aunis, D ;
Crémel, G ;
Hubert, P .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2004, 50 (01) :23-38
[4]  
BRETT AMO, 2003, ELECTROANAL, V15, P1
[5]  
Brett CMA, 1993, Electrochemistry: Principles, Methods, and Applications
[6]   Imatinib (STI571) induces DNA damage in BCR/ABL-expressing leukemic cells but not in normal lymphocytes [J].
Czechowska, A ;
Poplawski, T ;
Drzewoski, J ;
Blasiak, J .
CHEMICO-BIOLOGICAL INTERACTIONS, 2005, 152 (2-3) :139-150
[7]  
DICULESCU VC, 2006, IN PRESS BIOELECTROC
[8]   Tyrosine kinase inhibitors in the treatment of chronic myeloid leukaemia: so far so good? [J].
Drummond, MW ;
Holyoake, TL .
BLOOD REVIEWS, 2001, 15 (02) :85-95
[9]   Protein tyrosine kinase inhibitors: new treatment modalities? [J].
Fabbro, D ;
Parkinson, D ;
Matter, A .
CURRENT OPINION IN PHARMACOLOGY, 2002, 2 (04) :374-381
[10]   Direct and fast capillary zone electrophoretic method for the determination of Gleevec and its main metabolite in human urine [J].
Flores, JR ;
Berzas, J ;
Castañeda, G ;
Rodríguez, N .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2003, 794 (02) :381-388